Augustine Therapeutics
Leuven
About Augustine Therapeutics
Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $106.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2025)
- Website: augustinetx.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/augustine-therapeutics-17853 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.